ArticleKidney international2011
20-HETE in acute kidney injury.
Article in Kidney international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Molecular mechanisms of acute inflammation: systemic responses and kidney-specific pathophysiology.Function (Oxford, England) · 2026Review
- Integrated multi-sample transcriptomic analysis of COVID-19 patients against controls using a bioinformatics pipeline.Scientific reports · 2025Article
- Energy metabolic reprogramming regulates programmed cell death of renal tubular epithelial cells and might serve as a new therapeutic target for acute kidney injury.Frontiers in cell and developmental biology · 2023Review
- A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.Acta physiologica (Oxford, England) · 2019Article
- Arachidonic Acid Metabolism and Kidney Inflammation.International journal of molecular sciences · 2019Review
- Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.Journal of the American Society of Nephrology : JASN · 2017Review
- Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target.Pharmaceutics · 2017Review
- Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.Frontiers in bioscience (Landmark edition) · 2016Review
- Article
- Deficiency in the Formation of 20-Hydroxyeicosatetraenoic Acid Enhances Renal Ischemia-Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2015Article
- Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat.American journal of physiology. Regulatory, integrative and comparative physiology · 2015Article
- Cytochrome P450 eicosanoids in hypertension and renal disease.Current opinion in nephrology and hypertension · 2015Review
- Role of medullary blood flow in the pathogenesis of renal ischemia-reperfusion injury.Current opinion in nephrology and hypertension · 2012Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Ischemia/reperfusion injury (IRI) is a common cause of acute kidney injury (AKI) that is associated with a patient mortality of up to 50%. Currently there are not effective pharmacologic therapies for AKI. This Commentary highlights recent evidence indicating that 20-HETE plays an important role in IRI and that drugs that target this pathway have potential as therapeutic agents for AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.